From Liston Street Pulse:
There have been news/rumors that Amgen (AMGN) and Onyx (ONXX) are discussing the deal all over again and Amgen may raise the offer to $130 per share. While rejecting Amgen's earlier $120 offer, Onyx CEO said in a statement that it is "significantly undervalued." Is it? Onyx's three assets Kyprolis used for treating multiple myeloma […]
The post Onyx - Whose Take Is It Anyway? appeared first on Liston Street Pulse.
Created by Stock Researching | Dec 13, 2016
Created by Stock Researching | Dec 04, 2016
Created by Stock Researching | Dec 02, 2016
Created by Stock Researching | Nov 19, 2016
Created by Stock Researching | Nov 10, 2016
Created by Stock Researching | Oct 05, 2015